Antiverse

Investor: Soulmates Ventures

Antiverse, a biotech firm headquartered in Wales, has successfully completed a Series A funding round, securing £7 million to advance its AI-driven therapeutic antibody technology.Summary of transaction details:Value: £7,000,000Sector: Biotechnology / AI Drug DiscoveryAdvisor: Not specifiedKey Entities: Target: Antiverse; Lead Investor: Soulmates Ventures; Additional Investors: Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital, i&i Biotech FundLocation: Cardiff, UKNote: This significant capital injection will enable Antiverse to scale its generative antibody design platform, deepen strategic partnerships, and accelerate its mission to develop therapies for previously 'undruggable' molecular targets, solidifying its position in the drug discovery landscape.

Investor: Soulmates Ventures

Antiverse, a BioTech firm specializing in AI-designed therapeutic antibodies for undruggable disease targets, has successfully secured £7 million in a Series A funding round.Summary of transaction details:Value: £7 millionSector: BioTech / MedTechAdvisor: Not disclosedKey Entities: Target: Antiverse, Lead Investor: Soulmates VenturesLocation: Cardiff, UKNote: This significant investment will enable Antiverse to scale its discovery platform, accelerate its internal drug pipeline, and advance lead antibody programmes towards in vivo efficacy studies, including a new research agreement with the Cystic Fibrosis Foundation to target historically difficult proteins.

Investor: Soulmates Ventures

Antiverse, a UK-based biotech company, has closed a Series A funding round of £7 million led by Soulmates Ventures, with participation from other investors including Innovation Investment Capital, DOMiNO Ventures, and existing investors. Summary of transaction details: Value: £7 million Sector: Healthcare & Biotech Advisor: Not disclosed Key Entities: Antiverse, Soulmates Ventures, Innovation Investment Capital, DOMiNO Ventures, DBW, Kadmos Capital, i&i Biotech Fund Location: United Kingdom Note: This investment underscores the growing interest in biotech companies that utilize AI for therapeutic antibody development, highlighting the potential for such technologies to address previously undruggable disease targets.